CSIMarket
 
Fresenius Medical Care Ag  (FMS)
Other Ticker:  
 
    Sector  Healthcare    Industry Healthcare Facilities
   Industry Healthcare Facilities
   Sector  Healthcare
 
Price: $18.6000 $-0.17 -0.906%
Day's High: $18.665 Week Perf: -2.52 %
Day's Low: $ 18.48 30 Day Perf: -7.37 %
Volume (M): 347 52 Wk High: $ 27.72
Volume (M$): $ 6,462 52 Wk Avg: $21.43
Open: $18.63 52 Wk Low: $16.37



 Market Capitalization (Millions $) 5,457
 Shares Outstanding (Millions) 293
 Employees 1,254
 Revenues (TTM) (Millions $) 21,788
 Net Income (TTM) (Millions $) 820
 Cash Flow (TTM) (Millions $) 0
 Capital Exp. (TTM) (Millions $) 0

Fresenius Medical Care Ag
Fresenius Medical Care AG & Co. KGaA (FMC) is a global healthcare provider specializing in the treatment of chronic kidney disease (CKD), dialysis services, and renal care products. It was formed in 1996 when Fresenius SE acquired National Medical Care Inc. and merged it with its dialysis division in Germany. FMC is headquartered in Bad Homburg, Germany, and operates in more than 150 countries worldwide.

The company's primary mission is to enhance the quality of life of patients diagnosed with CKD, providing integrated services and innovative solutions for the early detection and treatment of the disease. FMC provides a broad range of services - including hemodialysis, home dialysis, peritoneal dialysis, and related products - to over 345,000 patients around the world, with a focus on providing high-quality care that is both affordable and accessible. FMC has well over 50 years of experience in dialysis and created the world's first automatic dialysis machine in 196

FMC's strategy is built around its Core Values of Quality, Accountability, Citizenship, and Passion. The company is committed to creating sustainable value for all stakeholders by maintaining a strong focus on operational excellence, continuous improvement, and innovation. The company is committed to delivering responsible business practices, ethically managed operations, and transparent financial reporting as a corporate citizen.

FMC has a diversified business model that includes the development and delivery of products and services, including dialysis machines, dialyzers, renal pharmaceuticals, and healthcare management software. The company's research and development efforts are focused on developing innovative treatments for kidney disease, including the use of stem cells in the regeneration of renal tissue.

FMC is listed on the Frankfurt Stock Exchange and the New York Stock Exchange under the ticker symbol FMS. It is a constituent of the DAX 30 index, the Euro Stoxx 50 index, and the S&P 500 index. The company generates approximately 70% of its revenue from its dialysis business, which remains a critical component of its growth strategy.

In conclusion, Fresenius Medical Care AG & Co. KGaA is a global healthcare provider focused on the treatment of chronic kidney disease. FMC provides a broad range of services and products to over 345,000 patients worldwide while maintaining a focus on operational excellence, innovation, and sustainable value creation. The company's diversified business model includes the development and delivery of dialysis machines, dialyzers, renal pharmaceuticals, healthcare management software, and research focused on developing innovative treatments for kidney disease. FMC's commitment to its core values, ethical practices and responsible corporate citizenship is a testament to the company's leadership as a global healthcare provider.


   Company Address: Else-Kröner-Strasse 1 Bad Homburg 61352
   Company Phone Number: 79 103 33 53   Stock Exchange / Ticker: NYSE FMS
   


Customers Net Income fell by FMS's Customers Net Profit Margin fell to

-11.47 %

2.77 %

• Customers Performance • Customers Expend. • Customers Efficiency • List of Customers


   

Stock Performances by Major Competitors

5 Days Decrease / Increase
     
DVA   -1.73%    
THC   -2.8%    
• View Complete Report
   



Fresenius Medical Care Ag

2. Fresenius Medical Care Ag Faces Challenges in Maintaining Profitability Amidst Revenue Growth Constraints

The recent financial report of Fresenius Medical Care Ag (FMS) for the fiscal fourth quarter of 2023 has shown a mixed bag of results. While there was a marginal increase in revenue of 0.287%, reaching $21.79 billion, the income saw a significant decline of -26.09% compared to the same period in the previous year. Earnings per share (EPS) also dropped to $1.90 from $2.58 in the preceding fiscal year.
The company's focus on improving sales in the October to December 31, 2023 period resulted in a net margin of 3.77%, a decrease from the 8.77% growth reported by other companies in the Healthcare Facilities industry. Operating earnings fell by -9.41% to $1533.77056 million, leading to a decrease in the operating margin to 7.04%.






 

Fresenius Medical Care Ag's Segments
 
 
• View Complete Report
  Company Estimates  
  Revenue Outlook
Fresenius Medical Care Ag does not provide revenue guidance.

Earnings Outlook
Fresenius Medical Care Ag does not provide earnings estimates.

 
Geographic Revenue Dispersion




Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com